Last update 22 Dec 2024
VC-005
Last update 22 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms VC 005, VC-005, VC005 |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
14
Clinical Trials associated with VC-005A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis
评价VC005凝胶在健康受试者及轻中度特应性皮炎患者中的单次和多次给药的安全、耐受性和药代动力学研究
[Translation] To evaluate the safety, tolerability and pharmacokinetics of VC005 gel after single and multiple administration in healthy subjects and patients with mild to moderate atopic dermatitis
100 Clinical Results associated with VC-005
Login to view more data
100 Translational Medicine associated with VC-005
Login to view more data
100 Patents (Medical) associated with VC-005
Login to view more data
100 Deals associated with VC-005
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 3 | CN | 30 Dec 2024 | |
| Severe Atopic Dermatitis | Phase 3 | CN | 30 Dec 2024 | |
| Ankylosing Spondylitis | Phase 2 | CN | - | 21 Apr 2023 |
| Mild Atopic Dermatitis | Phase 1 | CN | - | 26 Jul 2023 |
| Rheumatoid Arthritis | Phase 1 | CN | - | 06 Jun 2023 |
| Inflammation | Phase 1 | CN | 30 Jan 2022 | |
| Inflammatory Bowel Diseases | Phase 1 | CN | - | 02 Nov 2021 |
| Eczema | IND Approval | CN | 17 Mar 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05997927 (NEWS) Manual  | Phase 2 | - | lluspruwxn(bqatydgzpx) = 治疗12周时，VC005高中低三个剂量组均达到主要终点，对比安慰剂组，显著改善EASI评分，疗效呈现良好的剂量相关性。 csctaqehie (uhcctrlzcb ) Met View more | Positive | 20 Aug 2024 | ||
Placebo | |||||||
NCT05814939 (NEWS) Manual | Phase 2 | - | nedivttkas(lhibfejpon) = VC005不同剂量组的患者病情显著改善，低剂量组在主要疗效终点上相对安慰剂有统计学意义的疗效差异，与阳性对照托法替布相当；高剂量组与托法替布组相比未出现指标恶化。 qzfdisexad (ugvkofgqyx ) View more | Positive | 05 Jul 2024 | ||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free